卡培他滨与表柔比星分别联合多西紫杉醇治疗转移性乳腺癌临床疗效及生活质量分析  

Clinical Efficacy and Quality of Life of Capecitabine and Epirubicin Combined with Docetaxel for the Treatment of Metastatic Breast Cancer

作　　者：马必东 胡孝渠[2] 周斌[3] 黄平[4] Ma Bidong(Wenzhou Medical College,Wenzhou 32500)

机构地区：[1]温州医科大学,温州325000 [2]温州医科大学附属第一医院甲乳腺外科 [3]温州市中医院肿瘤科 [4]浙江省肿瘤医院胸部化疗科

出　　处：《数理医药学杂志》2018年第9期1345-1347,共3页Journal of Mathematical Medicine

摘　　要：目的:对转移性乳腺癌患者应用卡培他滨、表柔比星分别和多西紫杉醇联合医治的临床疗效及生活质量进行分析。方法:对某院2015年6月~2018年6月诊治转移性乳腺癌112例患者临床资料加以分析,按照临床不同医治方案分成两组,将56例行表柔比星和多西紫杉醇联合医治患者设为对照组,将56例行卡培他滨和多西紫杉醇联合医治患者设为观察组,对两组临床疗效、毒副反应及生活质量进行比对、分析。结果:观察组总有效率(96.43%)比对照组(80.36%)高,且毒副反应总发生率(8.93%)比对照组低(P<0.05);观察组总体健康得分较对照组高(P<0.05)。结论:对转移性乳腺癌患者应用卡培他滨和多西紫杉醇联合医治疗效显著,可减少毒副反应发生,且提高患者生活质量。Objective：To evaluate the clinical efficacy and quality of life of capecitabine and epirubicin combined with docetaxel for the treatment of metastatic breast cancer.Methods：The clinical data of 112 cases of metastatic breast cancer diagnosed and treated in a hospital from June 2017to June 2018were analyzed and divided into two groups according to different clinical treatment plans.56patients treated with epirubicin and docetaxel were set up as control group.For the control group,56 patients treated with capecitabine and docetaxel were set up as the observation group.The clinical efficacy,toxicity and quality of life of the two groups were compared and analyzed.Results：The total effective rate of observation group was 96.43%,which was higher than that of the control group（80.36%）,and the total incidence of toxic side effects was 8.93%,which was lower than that of the control group（P〈0.05）.The overall health score of the observation group was higher than that of the control group（P〈0.05）.Conclusion：The combination therapy of capsidine and docetaxel in patients with metastatic breast cancer has remarkable curative effect,which can reduce the occurrence of toxic and side reaction,and improve the quality of life of patients.

关 键 词：转移性乳腺癌 多西紫杉醇 卡培他滨 表柔比星 生活质量 

分 类 号：R737.9[医药卫生—肿瘤]